A5023938742- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Kruppel-like factors research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Male Reproductive Health Studies
- Acute Myeloid Leukemia Research
- MicroRNA in disease regulation
- Science and Education Research
- PI3K/AKT/mTOR signaling in cancer
- Epigenetics and DNA Methylation
- Sperm and Testicular Function
- Sexual Differentiation and Disorders
- Women's cancer prevention and management
- Cancer Cells and Metastasis
- Phytochemistry Medicinal Plant Applications
- Mesenchymal stem cell research
- Protein Kinase Regulation and GTPase Signaling
- Eosinophilic Disorders and Syndromes
Clinics Hospital of Ribeirão Preto
2010
Universidade de São Paulo
2010
Universidade Estadual Paulista (Unesp)
2009
Background Chronic myeloproliferative disorders (MPDs) are clonal haematopoietic stem cell malignancies characterised by an accumulation of mature myeloid cells in bone marrow and peripheral blood. Deregulation the apoptotic machinery may be associated with MPD physiopathology. Aims To evaluate expression death receptors' family members, mononuclear apoptosis resistance, JAK2 allele burden. Subjects Methods Bone progenitor CD34 were separated using Ficoll-hypaque protocol followed Miltenyi...
Apoptosis deregulation might have a role in the pathophysiology of polycythemia vera (PV). This study evaluated Bcl-2 molecule expression CD34+ cells and leukocytes 12 PV patients. Gene was investigated by real time PCR using SybrGreen Quantitect kit protein western-blotting. JAK2 V617F mutation detected according to Baxter et al (2005). from patients presented higher levels A1 Mcl-1 (median: 22.6 5.2, respectively) comparison with controls (0.9 0.5, p=0.004 p=0.020); while Bcl-xL decreased...
As previously shown, higher levels of NOTCH1 and increased NF-κB signaling is a distinctive feature the more primitive umbilical cord blood (UCB) CD34+ hematopoietic stem cells (HSCs), as compared to bone marrow (BM). Differences between BM UCB cell composition also account for this finding. The CD133 marker defines subset among HSC with proposed hemangioblast potential. To further evaluate molecular basis related characteristics CD133+ HSC, immunomagnetically purified human from were used...